• 한국응용곤충학회지
• /
• 제33권2호
• /
• pp.114-121
• /
• 1994

우리나라 남부지역 해송림에 피해를 주고 잇는 솔껍질깍지벌레으 해송 단목당 밀도가 추정되었다. 구피해자와 신규발생자에서 흉고직경 10cm내외의 공시목을 채취, 가해 약충의 서식가능 면적을 조사한 바 1차측지 밀도는 차이가 없었으나 2차측지 이하 부속지의 밀도는 구피해지가 낮았다. 약충의 분포양식은 양 지역의 고시목에서 유사한 형태를 나타냇으며 단목당 약충 추정수는 주간의 약충수에 비하야 구피해지에서는 10.8배 신규발생지에서는 13.1배로서 최소 4,200마리, 최대 208,500마리이었다. 오차범위 20%내에서 필요한 공시지의 수는 수관중분의 내부, 수관하부의 중부 및 내부에서 채취한 길이가 10~20cm, 20~30cn인 2차측지이하 부속지로서 각 21개 및 11개이었다. 알주머니는 단목당 63.6%가 주간에 분포하여 이중 가장 밀도가 높은 부위는 역지를 보유한 절간마디이었으며 이를 포함, 인접된 4개 절간에서의 밀도는 주간 전체 밀도의 약 37%이었다.

• Journal of Chest Surgery
• /
• 제33권8호
• /
• pp.662-668
• /
• 2000

Background: Many recent results of clinical trials show that pre-operative concurrent chemoradiotherapy and surgical resection could increase the survival of N2 positive stage IIIA non-small cell lung cancer. This study was performed to assess the feasibility, toxicity, and affect rates of concurrent chemoradiotherapy and surgical resection in N2 positive stage IIIA non-small cell lung cancer. Material and Method: Thirty-one patients who underwent preoperative concurrent chemoradiotherapy for N2 positive stage IIIA non-small-cell lung cancer from May 1997 to April 1999 were entered into the study. Mean age was 61 yrs(43∼70 yrs), There were 24 men and 7 women. The confirmation of N2 disease were achieved through mediastinoscopic biopsy(24) and CT scans(7). Induction was achieved by two cycles of cisplatin and etoposide(EP) plus concurrent chest radiotherapy to 45 Gy. Resections were done at 3 weeks after the complection of preoperative concurrent chemoradiotherapy. Resections were performed in 23 patients, excluding 5 refusals and 3 distant metastasis. Result: All patients were compled the thoracic radiotherapy except one who had distant metastasis. Twenty three patients were completed the planned 2 cycles of EP chemotherapy, and 8 patients were received only 1 cycle for severe side effects(6), refusal(1), and distant metastasis(1). There was one postoperative mortality, and the cause of death was ARDS. Three patients who had neutropenic fever and one patient who had radiation pneumonitis were required admission and treatment. Esophagitis was the most common acute side effect, but relatively well-tolerated in most patients. The complection rate of concurrent chemoradiotherapy was 74%, resection rate was 71%, pathologic complete remission rate was 13.6%, and pathologic down-staging rate was 68%. Conclusion: Morbidity related to each treatment was acceptable and many of the patients have benefited down staging of its disease. Further prospective, preferably randomized, clinical trials of larger scale may be warranted to confirm the actual benefit of preoperative concurrent chemoradiotherapy and surgical resection in N2-positive stage IIIA non-small cell lung cancer.